Kalaris Reports Q3 2026 Net Loss of $11.0 Million; Cash Runway Into 2028
Kalaris reported a Q3 2026 net loss of $11.0 million, down from $11.9 million a year earlier. The company had $82.9 million in cash as of September 30, expecting it to last into 2028. Phase 1b/2 TH103 study results are now expected in the second half of 2027 due to a supply issue. R&D expenses were $8.3 million, down from $9.1 million in Q3 2025.
How this was made
The 30-second read
Why it matters
The disclosed loss and cash position suggest short‑term pressure, but the successful technology transfer and planned Phase 3 start could be viewed as long‑term upside.
Market read
Primary earnings disclosure for a micro‑cap biotech; modest trading relevance.
What to watch
Potential positive perception from completed technology transfer to KBI Biopharma and upcoming Phase 3 initiation.
Background
Kalaris Therapeutics (KLRS) is a clinical‑stage biotech focused on eye disease treatments. The 8‑K filing provides its Q3 financials and updates on its TH103 program.
Ticker impact
Kalaris Therapeutics reported Q3 2026 net loss of $11.0M and cash runway into 2028, a fresh earnings disclosure for the microcap.
likely modest downside as investors digest the loss and cash position
Earnings miss is modest but cash balance is strong; market typically reacts negatively to loss without upside guidance.
Market effects
Limited impact on broader biotech sector; reinforces cash‑burn concerns for early‑stage ophthalmology firms.
Minor effect on US small‑cap biotech segment.
Low global relevance.
Counterpoint
Cash runway to 2028 may enable a future upside catalyst if Phase 3 initiates as planned.
Key entities
- companyKalaris Therapeutics, Inc.
Clinical‑stage biotech developing TH103 for neovascular age‑related macular degeneration.
- companyKBI Biopharma
Commercial‑scale drug substance manufacturer for Kalaris.